Second-line FOLFOX chemotherapy for advanced biliary tract cancer - Authors' reply
Authors
Lamarca, AngelaPalmer, D. H.
Wasan, H. S.
Ross, P. J.
Ma, Y. T.
Arora, A.
Falk, S.
Gillmore, R.
Wadsley, J.
Patel, K.
Anthoney, A.
Maraveyas, A.
Iveson, T.
Waters, J. S.
Hobbs, C.
Barber, S.
Ryder, W. D.
Ramage, J.
Davies, L. M.
Bridgewater, J. A
Valle, Juan W
Affiliation
Department of Medical Oncology, The Christie NHS Foundation Trust/Institute of Cancer Sciences, University of Manchester, Manchester M20 4BXIssue Date
2021
Metadata
Show full item recordAbstract
NoneCitation
Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors’ reply. The Lancet Oncology. 2021 Jul;22(7):e288–9.Journal
Lancet OncologyDOI
10.1016/s1470-2045(21)00341-7PubMed ID
34197751Additional Links
https://dx.doi.org/10.1016/s1470-2045(21)00341-7Type
OtherLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s1470-2045(21)00341-7